Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review
Population-based net survival is an important tool for assessing prognostic advances. The unbiased Pohar Perme Estimator (PPE) was suggested in 2012 and soon established itself as the gold standard for estimating net survival. This scoping review aims to know in which context this estimator is being...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/14/3304 |
| _version_ | 1797440480252788736 |
|---|---|
| author | Camila Macedo Lima Nagamine Bárbara Niegia Garcia de Goulart Patrícia Klarmann Ziegelmann |
| author_facet | Camila Macedo Lima Nagamine Bárbara Niegia Garcia de Goulart Patrícia Klarmann Ziegelmann |
| author_sort | Camila Macedo Lima Nagamine |
| collection | DOAJ |
| description | Population-based net survival is an important tool for assessing prognostic advances. The unbiased Pohar Perme Estimator (PPE) was suggested in 2012 and soon established itself as the gold standard for estimating net survival. This scoping review aims to know in which context this estimator is being used in the oncology area, what the authors point out as a justification for its use, and the limitations found. We searched PubMed, and the grey literature to answer the question: Have studies involving patients diagnosed with cancer used the PPE to estimate cancer-specific survival? How do they justify the use of the PPE and what are the limitations pointed out? Out of 295 screened, 85 studies were included in this review. The two main characteristics of the PPE mentioned by the studies as justification were the fact that it is an unbiased estimator (83.5%) and that it produces comparable estimates among populations with different mortality rates from causes other than cancer (36.47%). No study pointed to a limitation due to the use of PPE. As a conclusion, the Pohar Perme Estimator is the gold standard for estimating net survival and should be more used in oncology, especially when dealing with population-based studies where the follow-up time is long, making high the probability of death from causes other than cancer. |
| first_indexed | 2024-03-09T12:07:48Z |
| format | Article |
| id | doaj.art-8b21f6dc178a4cdeb1aaff860af698d4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:07:48Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8b21f6dc178a4cdeb1aaff860af698d42023-11-30T22:55:37ZengMDPI AGCancers2072-66942022-07-011414330410.3390/cancers14143304Net Survival in Survival Analyses for Patients with Cancer: A Scoping ReviewCamila Macedo Lima Nagamine0Bárbara Niegia Garcia de Goulart1Patrícia Klarmann Ziegelmann2Post-Graduate Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Bairro Santa Cecilia, Porto Alegre 90035-002, BrazilPost-Graduate Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Bairro Santa Cecilia, Porto Alegre 90035-002, BrazilPost-Graduate Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos, 2400, Bairro Santa Cecilia, Porto Alegre 90035-002, BrazilPopulation-based net survival is an important tool for assessing prognostic advances. The unbiased Pohar Perme Estimator (PPE) was suggested in 2012 and soon established itself as the gold standard for estimating net survival. This scoping review aims to know in which context this estimator is being used in the oncology area, what the authors point out as a justification for its use, and the limitations found. We searched PubMed, and the grey literature to answer the question: Have studies involving patients diagnosed with cancer used the PPE to estimate cancer-specific survival? How do they justify the use of the PPE and what are the limitations pointed out? Out of 295 screened, 85 studies were included in this review. The two main characteristics of the PPE mentioned by the studies as justification were the fact that it is an unbiased estimator (83.5%) and that it produces comparable estimates among populations with different mortality rates from causes other than cancer (36.47%). No study pointed to a limitation due to the use of PPE. As a conclusion, the Pohar Perme Estimator is the gold standard for estimating net survival and should be more used in oncology, especially when dealing with population-based studies where the follow-up time is long, making high the probability of death from causes other than cancer.https://www.mdpi.com/2072-6694/14/14/3304cancer survivalnet survivalcancer registriesepidemiologyPohar Perme Estimator |
| spellingShingle | Camila Macedo Lima Nagamine Bárbara Niegia Garcia de Goulart Patrícia Klarmann Ziegelmann Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review Cancers cancer survival net survival cancer registries epidemiology Pohar Perme Estimator |
| title | Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review |
| title_full | Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review |
| title_fullStr | Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review |
| title_full_unstemmed | Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review |
| title_short | Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review |
| title_sort | net survival in survival analyses for patients with cancer a scoping review |
| topic | cancer survival net survival cancer registries epidemiology Pohar Perme Estimator |
| url | https://www.mdpi.com/2072-6694/14/14/3304 |
| work_keys_str_mv | AT camilamacedolimanagamine netsurvivalinsurvivalanalysesforpatientswithcancerascopingreview AT barbaraniegiagarciadegoulart netsurvivalinsurvivalanalysesforpatientswithcancerascopingreview AT patriciaklarmannziegelmann netsurvivalinsurvivalanalysesforpatientswithcancerascopingreview |